INSM

$104.444.46%-4.87

Nachbörslich: 105.00+0.56 +0.54%

Insmed Inc (INSM)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$109.31

Offen:

$109.31

24-Stunden-Volumen:

6,218,048

Relatives Volumen:

1.30

Marktkapitalisierung:

$22.91B

Einnahmen:

$819.56M

Nettoeinkommen (Verlust:

-$1.18B

KGV:

EPS:

-$5.74

Netto-Cashflow:

-$951.64M

1W Leistung:

+9.98%

1M Leistung:

-6.01%

6M Leistung:

-21.63%

1Y Leistung:

-43.92%

1-Tages-Spanne:

$104.25$111.11

1-Wochen-Bereich:

$103.78$116.37

52-Wochen-Spanne:

$90.39$212.75

Insmed Inc Aktie (INSM) Unternehmensprofil

Firmenname

Insmed Inc

Sektor

Healthcare

Branche

Biotechnology

Telefon

908-977-9900

Adresse

700 US HIGHWAY 202/206, BRIDGEWATER, NJ, USA

Mitarbeiter

1,664

@insmed

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

INSM-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Insmed Inc Aktie (INSM) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-12	Herabstufung	Wolfe Research	Outperform → Peer Perform
2026-09-24	Resumed	Goldman	Buy
2026-07-21	Eingeleitet	BMO Capital Markets	Outperform
2026-04-10	Eingeleitet	Raymond James	Outperform
2026-03-30	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2026-03-16	Resumed	Jefferies	Buy
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-23	Eingeleitet	Roth Capital	Buy
2025-12-19	Resumed	Truist	Buy
2025-12-04	Eingeleitet	Rothschild & Co Redburn	Buy
2025-10-28	Resumed	Cantor Fitzgerald	Overweight
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-08-20	Eingeleitet	William Blair	Outperform
2025-08-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-05-13	Eingeleitet	Jefferies	Buy
2025-02-25	Eingeleitet	RBC Capital Mkts	Outperform
2024-04-23	Eingeleitet	Truist	Buy
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-20	Resumed	JP Morgan	Overweight
2023-07-26	Eingeleitet	Guggenheim	Buy
2022-12-09	Eingeleitet	Mizuho	Buy
2022-12-07	Eingeleitet	Barclays	Overweight
2022-11-18	Eingeleitet	BofA Securities	Buy
2022-04-27	Eingeleitet	Goldman	Buy
2021-12-06	Eingeleitet	JP Morgan	Overweight
2021-10-19	Resumed	Monness Crespi & Hardt	Buy
2021-10-19	Resumed	Morgan Stanley	Overweight
2021-10-08	Eingeleitet	Cantor Fitzgerald	Overweight
2021-04-26	Resumed	Credit Suisse	Outperform
2020-12-17	Eingeleitet	Berenberg	Buy
2020-10-12	Resumed	Stifel	Buy
2019-09-03	Eingeleitet	Goldman	Buy
2019-04-09	Bestätigt	H.C. Wainwright	Buy
2019-02-15	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2019-01-17	Hochstufung	Goldman	Neutral → Buy
2019-01-02	Eingeleitet	Canaccord Genuity	Buy
2018-08-06	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-07-23	Eingeleitet	Goldman	Neutral
2018-04-23	Hochstufung	Credit Suisse	Neutral → Outperform
2018-03-21	Eingeleitet	Morgan Stanley	Overweight
2018-01-18	Eingeleitet	Credit Suisse	Neutral
2017-09-05	Bestätigt	Evercore ISI	Outperform
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-07-11	Eingeleitet	Robert W. Baird	Outperform
2016-03-15	Eingeleitet	Stifel	Buy
2015-11-09	Herabstufung	UBS	Buy → Neutral
2015-10-06	Bestätigt	H.C. Wainwright	Buy
2015-06-09	Eingeleitet	Citigroup	Neutral
2014-03-26	Bestätigt	HC Wainwright	Buy

Finanzdaten der Insmed Inc-Aktie (INSM)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	606.42	363.71	305.21	245.36	188.46
Cost of revenue USD (M)	122.94	85.74	65.57	55.13	44.15
Gross profit USD (M)	-	-	239.64	190.23	144.31
Research and development USD (M)	771.09	598.37	571.01	397.52	272.74
Operating expenses USD (M)	1,853.19	1,241.96	949.26	647.55	519.40
Operating income USD (M)	-1,246.77	-878.25	-709.63	-457.32	-375.09
Income before tax USD (M)	-1,271.75	-910.07	-747.01	-480.15	-436.41
Income tax expense USD (M)	5.03	3.71	2.56	1.38	-1.76
Net income USD (M)	-1,276.78	-913.77	-749.57	-481.53	-434.65
Basic EPS USD/shares	-6.42	-5.57	-5.34	-3.91	-3.88
Diluted EPS USD/shares	-6.42	-5.57	-5.34	-3.91	-3.88
Basic weighted shares shares (M)	199.01	164.04	140.43	123.04	112.11
Diluted weighted shares shares (M)	199.01	164.04	140.43	123.04	112.11
Selling, general and administrative USD (M)	701.17	461.12	-	-	-

Insmed Inc-Aktie (INSM) Insiderhandel

Sara BonsteinNov 03 '26
Former Officer
Transaktion
Proposed Sale
Kosten
$109.31
#Aktien
10,261
Wert ($)
1,121,629
#Aktien Gesamt
0
Brennan David RSep 09 '26
Director
Transaktion
Sale
Kosten
$124.00
#Aktien
25,000
Wert ($)
3,100,000
#Aktien Gesamt
39,238
Brennan David RSep 09 '26
Director
Transaktion
Proposed Sale
Kosten
$123.99
#Aktien
25,000
Wert ($)
3,099,729
#Aktien Gesamt
0
SHAROKY MELVIN MDAug 17 '26
Director
Transaktion
Sale
Kosten
$127.53
#Aktien
5,000
Wert ($)
637,650
#Aktien Gesamt
0
MELVIN SHAROKYAug 17 '26
Director
Transaktion
Proposed Sale
Kosten
$127.53
#Aktien
5,000
Wert ($)
637,637
#Aktien Gesamt
0
Roger AdsettAug 10 '26
Officer
Transaktion
Proposed Sale
Kosten
$133.26
#Aktien
239,850
Wert ($)
31,963,198
#Aktien Gesamt
0
Adsett RogerAug 10 '26
Chief Operating Officer
Transaktion
Option Exercise
Kosten
$20.45
#Aktien
239,850
Wert ($)
4,905,570
#Aktien Gesamt
338,594
Adsett RogerAug 10 '26
Chief Operating Officer
Transaktion
Sale
Kosten
$133.27
#Aktien
239,850
Wert ($)
31,964,810
#Aktien Gesamt
98,744
Flammer Martina M.D.Aug 06 '26
Chief Medical Officer
Transaktion
Sale
Kosten
$128.61
#Aktien
27,173
Wert ($)
3,494,838
#Aktien Gesamt
60,486
Martina FlammerAug 06 '26
Officer
Transaktion
Proposed Sale
Kosten
$128.61
#Aktien
27,173
Wert ($)
3,494,755
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Sara Bonstein	Former Officer	Nov 03 '26	Proposed Sale	$109.31	10,261	1,121,629	0
Brennan David R	Director	Sep 09 '26	Sale	$124.00	25,000	3,100,000	39,238
Brennan David R	Director	Sep 09 '26	Proposed Sale	$123.99	25,000	3,099,729	0
SHAROKY MELVIN MD	Director	Aug 17 '26	Sale	$127.53	5,000	637,650	0
MELVIN SHAROKY	Director	Aug 17 '26	Proposed Sale	$127.53	5,000	637,637	0
Roger Adsett	Officer	Aug 10 '26	Proposed Sale	$133.26	239,850	31,963,198	0
Adsett Roger	Chief Operating Officer	Aug 10 '26	Option Exercise	$20.45	239,850	4,905,570	338,594
Adsett Roger	Chief Operating Officer	Aug 10 '26	Sale	$133.27	239,850	31,964,810	98,744
Flammer Martina M.D.	Chief Medical Officer	Aug 06 '26	Sale	$128.61	27,173	3,494,838	60,486
Martina Flammer	Officer	Aug 06 '26	Proposed Sale	$128.61	27,173	3,494,755	0

Insmed Inc Aktie (INSM) Neueste Nachrichten

Oct 30, 2026

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance - Zacks Investment Research

Oct 30, 2026

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat - Investing.com

Oct 30, 2026

Insmed shares fall as CFO Bonstein to exit Oct 30; 2026 guidance held - scanx.trade

Oct 30, 2026

Key facts: INSM $524.4M Q3 Rev; FDA Priority Review; $1.1B Cash - TradingView

Oct 30, 2026

Oct 29, 2026

Stifel cuts Insmed stock price target to $195 on OpEx outlook By Investing.com - Investing.com South Africa

Oct 29, 2026

Insmed Incorporated reports results for the quarter ended September 30 - Earnings Summary - TradingView

Oct 29, 2026

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status as ... - Yahoo Finance

Oct 29, 2026

Non-Cystic Fibrosis Bronchiectasis Pipeline Landscape 2026: Late-Stage Candidates, MOA Trends, and ROA | Insmed, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici - StreetInsider

Oct 29, 2026

Insmed Q3 Net Loss Narrows; Revenue Rises - www.marketscreener.com

Oct 29, 2026

Insmed jumps after strong Q3 revenue growth and higher 2026 product guidance - Quiver Quantitative

Oct 29, 2026

Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com

Oct 29, 2026

Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday - Benzinga

Oct 29, 2026

Earnings call transcript: Insmed Q3 2026 revenue beats as BRINSUPRI surges - Investing.com Canada

Oct 29, 2026

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Oct 29, 2026

Earnings Flash (INSM) Insmed Posts Q3 Loss $0.46 a Share, vs. FactSet Est of $0.38 Loss - marketscreener.com

Oct 29, 2026

Insmed Q3 2026 Earnings Call Is Live - TradingView

Oct 29, 2026

Why is Insmed stock surging today? By Investing.com - Investing.com Canada

Oct 29, 2026

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Oct 29, 2026

Insmed 3Q 2026: Revenue $524.4M, Net loss $100.3M, EPS $(0.46) — 10-Q Summary - TradingView

Oct 29, 2026

Insmed Q3 Revenue Reaches $524.4 Million as BRINSUPRI Sales Rise - Quiver Quantitative

Oct 29, 2026

Insmed: Q3 Earnings Snapshot - Yahoo Finance

Oct 29, 2026

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update - www.marketscreener.com

Oct 29, 2026

Insmed Reports Q3 Revenue of $524.4 Million and Raises 2026 Guidance - TradingView

Oct 29, 2026

Insmed Incorporated (INSM) Q3 Revenue $524.4M; Raises 2026 Guidance - TradingView

Oct 29, 2026

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update - TradingView

Oct 29, 2026

Oct 28, 2026

Insmed set to report earnings as Japan launch tests growth story By Investing.com - Investing.com South Africa

Oct 28, 2026

Insmed set to report earnings as Japan launch tests growth story - Investing.com

Oct 28, 2026

Oct 27, 2026

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know - Zacks Investment Research

Oct 27, 2026

H.C. Wainwright reiterates Insmed stock rating on pipeline progress By Investing.com - Investing.com Canada

Oct 27, 2026

Oct 23, 2026

Insmed Incorporated Estimates – BMV:INSM - TradingView

Oct 23, 2026

Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Australia

Oct 23, 2026

Al Sandrock to step down as Voyager CEO; Insmed adds Paul Hudson to board - Endpoints News

Oct 23, 2026

Oct 22, 2026

$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 22, 2026

The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media

Oct 22, 2026

Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board - ROI-NJ

Oct 22, 2026

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 22, 2026

Oct 21, 2026

Insmed Needs Brinsupri To Prove Its Organic Ramp After A 25% Post-Raise Slide - Finviz

Oct 21, 2026

Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com South Africa

Oct 21, 2026

Oct 20, 2026

Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com Canada

Oct 20, 2026

Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities - Kalkine Media

Oct 20, 2026

Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations

Oct 20, 2026

Form 8K Insmed Inc For: 20 October By Investing.com - Investing.com Nigeria

Oct 20, 2026

Insmed adds two directors with pharma leadership experience - Investing.com

Oct 20, 2026

Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView

Oct 20, 2026

Insmed adds two independent directors with biopharma backgrounds - StreetInsider

Oct 20, 2026

Insmed Appoints Two New Directors to Its Board - Yahoo Finance

Oct 20, 2026

Ähnlich wie INSM

Insmed Inc (INSM)

Insmed Inc Aktie (INSM) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Insmed Inc Aktie (INSM) Hochstufungen & Herabstufungen

Finanzdaten der Insmed Inc-Aktie (INSM)

Insmed Inc-Aktie (INSM) Insiderhandel

Insmed Inc Aktie (INSM) Neueste Nachrichten

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance - Zacks Investment Research

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat - Investing.com

Insmed shares fall as CFO Bonstein to exit Oct 30; 2026 guidance held - scanx.trade

Key facts: INSM $524.4M Q3 Rev; FDA Priority Review; $1.1B Cash - TradingView

Stifel cuts Insmed stock price target to $195 on OpEx outlook By Investing.com - Investing.com South Africa

Insmed Incorporated reports results for the quarter ended September 30 - Earnings Summary - TradingView

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status as ... - Yahoo Finance

What Insmed (INSM) Said on Its Q3 Earnings Call - Yahoo Finance

INSM Stock Jumps As BRINSUPRI Rollout Expands Globally - StocksToTrade

Insmed surges on Q3 revenue beats, revenue guidance range raise - TradingView

Non-Cystic Fibrosis Bronchiectasis Pipeline Landscape 2026: Late-Stage Candidates, MOA Trends, and ROA | Insmed, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici - StreetInsider

Insmed Q3 Net Loss Narrows; Revenue Rises - www.marketscreener.com

Insmed jumps after strong Q3 revenue growth and higher 2026 product guidance - Quiver Quantitative

Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com

Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday - Benzinga

Earnings call transcript: Insmed Q3 2026 revenue beats as BRINSUPRI surges - Investing.com Canada

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Earnings Flash (INSM) Insmed Posts Q3 Loss $0.46 a Share, vs. FactSet Est of $0.38 Loss - marketscreener.com

Insmed Q3 2026 Earnings Call Is Live - TradingView

Why is Insmed stock surging today? By Investing.com - Investing.com Canada

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Insmed 3Q 2026: Revenue $524.4M, Net loss $100.3M, EPS $(0.46) — 10-Q Summary - TradingView

Insmed Q3 Revenue Reaches $524.4 Million as BRINSUPRI Sales Rise - Quiver Quantitative

Insmed: Q3 Earnings Snapshot - Yahoo Finance

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update - www.marketscreener.com

Insmed Reports Q3 Revenue of $524.4 Million and Raises 2026 Guidance - TradingView

Insmed Incorporated (INSM) Q3 Revenue $524.4M; Raises 2026 Guidance - TradingView

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update - TradingView

Insmed set to report earnings as Japan launch tests growth story By Investing.com - Investing.com South Africa

Insmed set to report earnings as Japan launch tests growth story - Investing.com

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know - Zacks Investment Research

H.C. Wainwright reiterates Insmed stock rating on pipeline progress By Investing.com - Investing.com Canada

Insmed Incorporated Estimates – BMV:INSM - TradingView

Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Australia

Al Sandrock to step down as Voyager CEO; Insmed adds Paul Hudson to board - Endpoints News

$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Benzinga

The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media

Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board - ROI-NJ

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks Investment Research

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Insmed Needs Brinsupri To Prove Its Organic Ramp After A 25% Post-Raise Slide - Finviz

Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com South Africa

Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com Canada

Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities - Kalkine Media

Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations

Form 8K Insmed Inc For: 20 October By Investing.com - Investing.com Nigeria

Insmed adds two directors with pharma leadership experience - Investing.com

Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView

Insmed adds two independent directors with biopharma backgrounds - StreetInsider

Insmed Appoints Two New Directors to Its Board - Yahoo Finance

Ähnlich wie INSM